Development of nanocomposites for solid cancer treatment...Presenting a wide range of cancer treatment strategies
Mar 05, 2025
|
The study was led by Kyung Hee University College of Pharmacy researcher Jeong Yoon-hwa (doctor's program) and biopharmaceutical students Seo Min-ho (master's program) and Servison (academic program) at Konkuk University's Glocal Campus, and was published online in global journals in the field of nanoscience in recognition of their excellence. Immediately after its disclosure, the researchers who led the study were recently listed in the Center for Biological Research Information (BRIC) 'People Who Shined Korea (Hanbitsa).'
Common chemotherapy uses cocktail therapy that combines two to three anticancer drugs in patients to suppress anticancer drug resistance. Researchers at both institutions have developed a new nanoparticle that combines the anticoagulant 'heparin', multiple myeloma treatment 'renalidomide', and anti-cancer drug 'toxorubicin'.
The newly developed nanoparticle consists of only three drugs with different functions approved by the Ministry of Food and Drug Safety and the U.S. Food and Drug Administration (FDA), and is an original material composed of 100% drug components. The developed nanomaterials have significantly increased anticancer effects, especially in solid cancer, and have improved anticancer immune responses, which are important in anticancer treatment.
Lenalidomide is a drug that has not been tried well because it has side effects such as low efficacy and the risk of thrombosis when used alone in solid cancer treatment. However, the newly developed nanoparticles are designed to solve the problem of drug concentration reduction occurring in the existing drug delivery method and maximize the treatment effect. It also strengthened the immune control function of lenalidomide, expanding the possibility of using lenalidomide, which showed limitations in treating solid cancer. Heparin contained in nanoparticles acted as an anticoagulant, mitigating the risk of thrombosis, a representative side effect of lenalidomide.
This study has great implications by expanding the applicability of lenalidomide-based immunotherapy to solid cancer and presenting a new anticancer cocktail nanocomposite that self-assembles without delivery. The research team expected the results to present important research directions in various cancer treatment strategies in the future.
|
This article was translated by Naver AI translator.
